We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis.
The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What are the limitations of broad based immunotherapies in the treatment of myasthenia gravis (MG)? (0:18)
- What is nipocalimab and what is its mechanism of action? (2:52)
- Could you tell us a little about the Vivacity study and its efficacy and safety findings to date? (3:21)
- What questions remain unanswered about the clinical utility of nipocalimab in this treatment setting and what future studies are planned? (5:32)
- Where do you think nipocalimab will sit in the treatment paradigm for MG? (7:02)
Disclosures: Jeffrey Guptill is a consultant in past 12 months for Immunovant, Alexion, Apellis, Momenta, Ra Pharma, Grifols, Jacobus, Becton Dickinson, Cabaletta, Regeneron, Argenx, UCB, Toleranzia and Piedmont Pharmaceuticals; receives industry grant support from UCB pharma for a fellowship training grant. Full disclosure statement available at: https://dcri.org/about-us/conflict-of-interest/. Jeffrey Guptill is also a site investigator for: Alexion, Momenta, Ra Pharma, Argenx, Takeda, and receives grant/research support from: NIH (NIAID, NINDS, NIMH), and Myasthenia Gravis Foundation of America.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch,
Filmed as a highlight of AAN Annual Virtual Meeting 2021
